Impact of alfuzosin on sexual function in Taiwanese men with benign prostatic hyperplasia

Thomas Is Hwang, Sheng Hsien Chu, Mao Sheng Lin, Chih Shou Chen, Liang Ming Lee, Hong Chiang Chang, Shauh Der Yeh, Wen Hsiang Chen, Po Hui Chiang

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

To assess the effect of alfuzosin (XATRAL) 10 mg once daily on sexual function in men with moderate to severe lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), patients with suggestive symptomatic BPH, an International Prostate Symptom Score (IPSS) >8 (range of scores, 0-35), and sexual attempts at least once per month were enrolled. All patients received alfuzosin 10 mg once daily for 24 weeks and were asked to complete the IPSS test and Male Sexual Health Questionnaire at weeks 0 (baseline), 1, 4, 12, and 24. Other assessments included the International Index of Erectile Function - five-item version (range of scores: 5-25), as well as onset of action and peak urinary flow rate (Qmax). From September 2006 to May 2008, 279 patients were enrolled from nine centers in Taiwan. At 24 weeks, alfuzosin effectively improved LUTS and quality of life, as demonstrated by a reduction in the IPSS total score (17.3 vs. 9.9, p <0.001) and the IPSS bother score (3.8 vs. 2.5, p <0.001). The majority (85%) of patients perceived an improvement of urinary symptoms within 1 month of administration. In patients with an International Index of Erectile Function - five-item version score of ≤16, alfuzosin significantly improved erectile disorder and satisfaction subscores at each time point (p ≤ 0.02). Prolonged-release alfuzosin effectively improved LUTS, quality of life, erectile function, and sexual satisfaction in men with BPH and mild to severe erectile dysfunction. Alfuzosin is an effective treatment option for the management of patients with BPH/LUTS and concomitant sexual dysfunction.

Original languageEnglish
Pages (from-to)429-434
Number of pages6
JournalKaohsiung Journal of Medical Sciences
Volume28
Issue number8
DOIs
Publication statusPublished - Aug 2012

Fingerprint

Prostatic Hyperplasia
Lower Urinary Tract Symptoms
Prostate
Quality of Life
Orgasm
Reproductive Health
Erectile Dysfunction
Taiwan
alfuzosin

Keywords

  • Alfuzosin
  • Benign prostatic hyperplasia
  • Lower urinary tract symptoms
  • Sexual dysfunction

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hwang, T. I., Chu, S. H., Lin, M. S., Chen, C. S., Lee, L. M., Chang, H. C., ... Chiang, P. H. (2012). Impact of alfuzosin on sexual function in Taiwanese men with benign prostatic hyperplasia. Kaohsiung Journal of Medical Sciences, 28(8), 429-434. https://doi.org/10.1016/j.kjms.2012.02.013

Impact of alfuzosin on sexual function in Taiwanese men with benign prostatic hyperplasia. / Hwang, Thomas Is; Chu, Sheng Hsien; Lin, Mao Sheng; Chen, Chih Shou; Lee, Liang Ming; Chang, Hong Chiang; Yeh, Shauh Der; Chen, Wen Hsiang; Chiang, Po Hui.

In: Kaohsiung Journal of Medical Sciences, Vol. 28, No. 8, 08.2012, p. 429-434.

Research output: Contribution to journalArticle

Hwang, TI, Chu, SH, Lin, MS, Chen, CS, Lee, LM, Chang, HC, Yeh, SD, Chen, WH & Chiang, PH 2012, 'Impact of alfuzosin on sexual function in Taiwanese men with benign prostatic hyperplasia', Kaohsiung Journal of Medical Sciences, vol. 28, no. 8, pp. 429-434. https://doi.org/10.1016/j.kjms.2012.02.013
Hwang, Thomas Is ; Chu, Sheng Hsien ; Lin, Mao Sheng ; Chen, Chih Shou ; Lee, Liang Ming ; Chang, Hong Chiang ; Yeh, Shauh Der ; Chen, Wen Hsiang ; Chiang, Po Hui. / Impact of alfuzosin on sexual function in Taiwanese men with benign prostatic hyperplasia. In: Kaohsiung Journal of Medical Sciences. 2012 ; Vol. 28, No. 8. pp. 429-434.
@article{0efa048f015047ccbdb8155944bf4cab,
title = "Impact of alfuzosin on sexual function in Taiwanese men with benign prostatic hyperplasia",
abstract = "To assess the effect of alfuzosin (XATRAL) 10 mg once daily on sexual function in men with moderate to severe lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), patients with suggestive symptomatic BPH, an International Prostate Symptom Score (IPSS) >8 (range of scores, 0-35), and sexual attempts at least once per month were enrolled. All patients received alfuzosin 10 mg once daily for 24 weeks and were asked to complete the IPSS test and Male Sexual Health Questionnaire at weeks 0 (baseline), 1, 4, 12, and 24. Other assessments included the International Index of Erectile Function - five-item version (range of scores: 5-25), as well as onset of action and peak urinary flow rate (Qmax). From September 2006 to May 2008, 279 patients were enrolled from nine centers in Taiwan. At 24 weeks, alfuzosin effectively improved LUTS and quality of life, as demonstrated by a reduction in the IPSS total score (17.3 vs. 9.9, p <0.001) and the IPSS bother score (3.8 vs. 2.5, p <0.001). The majority (85{\%}) of patients perceived an improvement of urinary symptoms within 1 month of administration. In patients with an International Index of Erectile Function - five-item version score of ≤16, alfuzosin significantly improved erectile disorder and satisfaction subscores at each time point (p ≤ 0.02). Prolonged-release alfuzosin effectively improved LUTS, quality of life, erectile function, and sexual satisfaction in men with BPH and mild to severe erectile dysfunction. Alfuzosin is an effective treatment option for the management of patients with BPH/LUTS and concomitant sexual dysfunction.",
keywords = "Alfuzosin, Benign prostatic hyperplasia, Lower urinary tract symptoms, Sexual dysfunction",
author = "Hwang, {Thomas Is} and Chu, {Sheng Hsien} and Lin, {Mao Sheng} and Chen, {Chih Shou} and Lee, {Liang Ming} and Chang, {Hong Chiang} and Yeh, {Shauh Der} and Chen, {Wen Hsiang} and Chiang, {Po Hui}",
year = "2012",
month = "8",
doi = "10.1016/j.kjms.2012.02.013",
language = "English",
volume = "28",
pages = "429--434",
journal = "Gaoxiong yi xue ke xue za zhi = The Kaohsiung journal of medical sciences",
issn = "1607-551X",
publisher = "高雄醫學大學",
number = "8",

}

TY - JOUR

T1 - Impact of alfuzosin on sexual function in Taiwanese men with benign prostatic hyperplasia

AU - Hwang, Thomas Is

AU - Chu, Sheng Hsien

AU - Lin, Mao Sheng

AU - Chen, Chih Shou

AU - Lee, Liang Ming

AU - Chang, Hong Chiang

AU - Yeh, Shauh Der

AU - Chen, Wen Hsiang

AU - Chiang, Po Hui

PY - 2012/8

Y1 - 2012/8

N2 - To assess the effect of alfuzosin (XATRAL) 10 mg once daily on sexual function in men with moderate to severe lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), patients with suggestive symptomatic BPH, an International Prostate Symptom Score (IPSS) >8 (range of scores, 0-35), and sexual attempts at least once per month were enrolled. All patients received alfuzosin 10 mg once daily for 24 weeks and were asked to complete the IPSS test and Male Sexual Health Questionnaire at weeks 0 (baseline), 1, 4, 12, and 24. Other assessments included the International Index of Erectile Function - five-item version (range of scores: 5-25), as well as onset of action and peak urinary flow rate (Qmax). From September 2006 to May 2008, 279 patients were enrolled from nine centers in Taiwan. At 24 weeks, alfuzosin effectively improved LUTS and quality of life, as demonstrated by a reduction in the IPSS total score (17.3 vs. 9.9, p <0.001) and the IPSS bother score (3.8 vs. 2.5, p <0.001). The majority (85%) of patients perceived an improvement of urinary symptoms within 1 month of administration. In patients with an International Index of Erectile Function - five-item version score of ≤16, alfuzosin significantly improved erectile disorder and satisfaction subscores at each time point (p ≤ 0.02). Prolonged-release alfuzosin effectively improved LUTS, quality of life, erectile function, and sexual satisfaction in men with BPH and mild to severe erectile dysfunction. Alfuzosin is an effective treatment option for the management of patients with BPH/LUTS and concomitant sexual dysfunction.

AB - To assess the effect of alfuzosin (XATRAL) 10 mg once daily on sexual function in men with moderate to severe lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), patients with suggestive symptomatic BPH, an International Prostate Symptom Score (IPSS) >8 (range of scores, 0-35), and sexual attempts at least once per month were enrolled. All patients received alfuzosin 10 mg once daily for 24 weeks and were asked to complete the IPSS test and Male Sexual Health Questionnaire at weeks 0 (baseline), 1, 4, 12, and 24. Other assessments included the International Index of Erectile Function - five-item version (range of scores: 5-25), as well as onset of action and peak urinary flow rate (Qmax). From September 2006 to May 2008, 279 patients were enrolled from nine centers in Taiwan. At 24 weeks, alfuzosin effectively improved LUTS and quality of life, as demonstrated by a reduction in the IPSS total score (17.3 vs. 9.9, p <0.001) and the IPSS bother score (3.8 vs. 2.5, p <0.001). The majority (85%) of patients perceived an improvement of urinary symptoms within 1 month of administration. In patients with an International Index of Erectile Function - five-item version score of ≤16, alfuzosin significantly improved erectile disorder and satisfaction subscores at each time point (p ≤ 0.02). Prolonged-release alfuzosin effectively improved LUTS, quality of life, erectile function, and sexual satisfaction in men with BPH and mild to severe erectile dysfunction. Alfuzosin is an effective treatment option for the management of patients with BPH/LUTS and concomitant sexual dysfunction.

KW - Alfuzosin

KW - Benign prostatic hyperplasia

KW - Lower urinary tract symptoms

KW - Sexual dysfunction

UR - http://www.scopus.com/inward/record.url?scp=84865043280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865043280&partnerID=8YFLogxK

U2 - 10.1016/j.kjms.2012.02.013

DO - 10.1016/j.kjms.2012.02.013

M3 - Article

VL - 28

SP - 429

EP - 434

JO - Gaoxiong yi xue ke xue za zhi = The Kaohsiung journal of medical sciences

JF - Gaoxiong yi xue ke xue za zhi = The Kaohsiung journal of medical sciences

SN - 1607-551X

IS - 8

ER -